Gynecologic Oncology Reports最新文献

{"title":"Utility of computerized tomography in clinical staging and surgical decision making in patients with uterine cancer","authors":"Andrew Tannous ,&nbsp;Alexzandra Adler ,&nbsp;Jeanelle Sheeder ,&nbsp;Rebecca J. Wolsky ,&nbsp;Jill Alldredge","doi":"10.1016/j.gore.2025.101812","DOIUrl":"10.1016/j.gore.2025.101812","url":null,"abstract":"<div><h3>Objective</h3><div>We investigated the utility of pre-operative computerized tomography (CT) abdomen and pelvis on clinical staging and surgical decision making for uterine carcinoma.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients treated surgically for uterine carcinoma between 2010 and 2021 at a single academic center. Data on patient demographics, tumor characteristics, CT imaging results, and surgical procedures were collected. Diagnostic accuracy metrics (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV]) were analyzed to assess the predictive value of CT for determining extrauterine disease, lymphadenopathy, and omental involvement. The impact of CT imaging on surgical management decisions was also evaluated.</div></div><div><h3>Results</h3><div>Of 409 patients meeting inclusion criteria, 68.9 % underwent pre-operative CT imaging. CT demonstrated moderate sensitivity (67.0 %, 61/91) and high specificity (87.4 %, 145/166) for detecting extrauterine disease, which was comparable across those with low grade endometrioid, high grade endometrioid, and non-endometrioid histotypes. Patients with abnormal CT findings were significantly more likely to have advanced stage disease (FIGO stage III/IV; p &lt; 0.001), undergo tumor debulking (p &lt; 0.001), and receive pelvic (p = 0.001) and <em>para</em>-aortic lymphadenectomy (p &lt; 0.001). Conversely, patients with normal CT scans more frequently underwent minimally invasive surgery (MIS) and sentinel lymph node (SLN) procedures (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Preoperative CT shows moderate sensitivity but high specificity for identifying extrauterine disease in uterine carcinoma, supporting continued use for high risk histotypes. Among patients with low-grade histotypes, risk-adaptive use of CT may be valuable in determining eligibility for either MIS or SLN mapping. This is an increasingly relevant consideration as MIS and SLN are becoming more widely adopted.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101812"},"PeriodicalIF":1.2,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response of somatic POLE-ultramutated recurrent undifferentiated uterine sarcoma to pembrolizumab and concurrent radiotherapy","authors":"Natasha E. Charewycz ,&nbsp;I-Chow Joe Hsu ,&nbsp;Kevin Lu ,&nbsp;Katherine Fuh ,&nbsp;Lee-may Chen ,&nbsp;Varun Monga ,&nbsp;Stephanie Cham","doi":"10.1016/j.gore.2025.101814","DOIUrl":"10.1016/j.gore.2025.101814","url":null,"abstract":"<div><h3>Objectives</h3><div>To discuss the role of immunotherapy and concurrent radiotherapy in the treatment of <em>POLE</em>-ultramutated undifferentiated uterine sarcoma (UUS).</div></div><div><h3>Methods</h3><div>We present the case of a woman with rapidly recurrent <em>POLE</em>-ultramutated UUS who exhibited a complete response to treatment with pembrolizumab and concurrent radiotherapy.</div></div><div><h3>Results</h3><div>A 67-year-old woman diagnosed with stage IB UUS underwent surgical resection with negative margins and experienced rapid locoregional recurrence within six weeks. Next-generation sequencing (NGS) identified a somatic <em>POLE</em> mutation (p.V411L) and high tumor mutational burden (171 mutations/Mb), classifying the tumor as <em>POLE</em>-ultramutated. The patient was subsequently treated with concurrent radiation and pembrolizumab and demonstrated complete disease resolution after cycle 3 of pembrolizumab and one month post-radiation completion. She has since remained disease-free for 17 months on pembrolizumab maintenance therapy.</div></div><div><h3>Conclusions</h3><div>To our knowledge, this is the first reported case of a <em>POLE</em>-ultramutated uterine sarcoma, and it highlights a striking and durable response to immunotherapy in combination with radiation. This case underscores the potential value of comprehensive molecular profiling in uterine sarcomas to guide personalized treatment approaches. <em>POLE</em>-ultramutated status, previously characterized in endometrial carcinoma as a favorable prognostic biomarker, may have therapeutic implications in other gynecologic and soft tissue sarcomas. Further investigation into the prevalence and significance of <em>POLE</em> mutations in sarcomas is warranted, along with continued exploration of immunotherapy and radiation synergy in this context.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101814"},"PeriodicalIF":1.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144685696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain metastatic GTN treated without radiotherapy: Case report","authors":"Soheila Aminimoghaddam,&nbsp;Maryam Ghoreyshi,&nbsp;Alireza Zakaryaei,&nbsp;Elahe Ghaderi","doi":"10.1016/j.gore.2025.101813","DOIUrl":"10.1016/j.gore.2025.101813","url":null,"abstract":"<div><h3>Background</h3><div>Choriocarcinoma is a rare, aggressive form of gestational trophoblastic neoplasia (GTN) that may metastasize to the brain in advanced stages. Brain involvement typically manifests as intracerebral hemorrhage and is associated with high morbidity and mortality. While whole brain radiotherapy (WBRT) remains a standard adjunct to chemotherapy, it carries significant long-term neurocognitive risks.</div></div><div><h3>Case presentation</h3><div>We report the case of a 28-year-old female who presented with neurological symptoms caused by a hemorrhagic brain metastasis from choriocarcinoma. Emergency craniotomy was performed to evacuate the hematoma and resect the tumor. Histopathology confirmed metastatic choriocarcinoma. The patient received systemic multi-agent chemotherapy using EMA-CO and EMA-EP regimens, without WBRT or intrathecal chemotherapy. Serum hCG levels normalized, and follow-up imaging showed no recurrence, indicating complete remission.</div></div><div><h3>Conclusion</h3><div>This case highlights the potential for complete remission in brain metastatic choriocarcinoma using a treatment strategy that combines emergency neurosurgical intervention and systemic chemotherapy alone. Avoiding WBRT may reduce long-term cognitive complications in selected patients. A multidisciplinary approach remains essential in the management of high-risk GTN.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101813"},"PeriodicalIF":1.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144678821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of social vulnerability with access to treatment in ovarian cancer patients","authors":"Nikita Bastin ,&nbsp;Marc Robinson ,&nbsp;Amir Javid ,&nbsp;Lauren S. Prescott ,&nbsp;Alaina J. Brown","doi":"10.1016/j.gore.2025.101808","DOIUrl":"10.1016/j.gore.2025.101808","url":null,"abstract":"<div><h3>Objectives</h3><div>To understand disparities in access to treatment for ovarian cancer patients.</div></div><div><h3>Methods</h3><div>A retrospective review of patients who had surgery for ovarian cancer at a comprehensive cancer center from 2018 to 2024 was completed. Social Vulnerability index quartiles generated by patients’ zip codes were used as measures of social vulnerability. Social vulnerability encompasses four themes, including socioeconomic status, household characteristics, racial/ethnic minority status, and housing type and transportation. The primary outcome was time to treatment initiation. Secondary outcomes included time to chemotherapy, time to surgery, time to palliative care treatment, and progression-free survival. Logistic regression was used to assess the relationship between social vulnerability and treatment access.</div></div><div><h3>Results</h3><div>Among 166 ovarian cancer patients, there was a trend towards increased time from diagnosis to treatment amongst patients with the highest social vulnerability (median 40 days) when compared to those with lower social vulnerability (median 22 – 27 days). When examining specific treatments received, patients with lower social vulnerability were more likely to experience shorter times to chemotherapy (median 29.5–32 days) when compared to patients with higher social vulnerability (median 41 – 45 days). Patients with the highest social vulnerability experienced the longest time to surgery (median 128 days) amongst all quartiles. There was a trend towards shorter times from diagnosis to palliative care consultation for patients of higher social vulnerability.</div></div><div><h3>Conclusions</h3><div>Higher social vulnerability was associated with longer times to curative treatment and shorter times to palliative care consultation among ovarian cancer patients. Further study in more diverse patient populations is necessary to ensure the equitable delivery of care in ovarian cancer.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101808"},"PeriodicalIF":1.2,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience","authors":"Helen Toma ,&nbsp;Rebeca Kelly ,&nbsp;Chelsea Katz ,&nbsp;Hannah Hong ,&nbsp;Hannah Diasti ,&nbsp;David P. Warshal ,&nbsp;Lauren Krill","doi":"10.1016/j.gore.2025.101811","DOIUrl":"10.1016/j.gore.2025.101811","url":null,"abstract":"<div><h3>Background</h3><div>Advanced stage ovarian carcinoma has a poor prognosis with recurrence rates of over 80%, 5-year survival of 36–45%, and limited response to standard therapy. Pembrolizumab and lenvatinib are FDA approved for treatment of microsatellite stable (MSS)/mismatch repair proficient (pMMR) endometrial and renal cell cancers. Early phase II studies have shown promising results in a variety of advanced solid tumors, including ovarian cancer. We report on the clinical outcome of recurrent MSS/pMMR ovarian cancer patients treated with this therapy.</div></div><div><h3>Methods</h3><div>For this retrospective cohort study, patients with a diagnosis of ovarian cancer treated with pembrolizumab and lenvatinib from January 2020 to April 2024 at MD Anderson Cancer Center at Cooper were identified. Demographic data, tumor characteristics, germline/somatic genetic testing, treatment duration, and toxicity were collected. Response rate by RECIST criteria, progression free survival (PFS), and clinical benefit rate were calculated.</div></div><div><h3>Results</h3><div>Sixteen patients were identified. Most had high-grade serous (n = 11, 68.75 %) or clear cell histologies (n = 4, 25 %) and FIGO stage III/IV disease (n = 15, 93.75 %). Eighty-one percent had platinum resistant recurrent disease. Three patients discontinued therapy after one cycle, unrelated to drug toxicity, and were non-evaluable for response. Of 13 patients evaluable for response, 54 % had a partial response and 31 % had stable disease. The 6-month clinical benefit rate was 69 %. The median PFS for all evaluable patients was 7.9 months. At the time of data analysis, 2 patients remained on treatment.</div></div><div><h3>Conclusion</h3><div>Pembrolizumab-lenvatinib therapy demonstrated favorable clinical benefit in recurrent, platinum resistant MSS/pMMR ovarian cancer, a group of patients in need of more therapeutic options.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101811"},"PeriodicalIF":1.2,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of fatigue in gynaecological cancer: A feasibility study of an app-based exercise and mindfulness intervention","authors":"Kairen McCloy ,&nbsp;Ciara Hughes ,&nbsp;Lynn Dunwoody ,&nbsp;Joanne Marley ,&nbsp;Ian Cleland ,&nbsp;Federico Cruciani ,&nbsp;Jackie Gracey","doi":"10.1016/j.gore.2025.101807","DOIUrl":"10.1016/j.gore.2025.101807","url":null,"abstract":"<div><h3>Objectives</h3><div>Cancer-related fatigue (CRF) is an issue for many people living with and beyond cancer. Evidence suggests that exercise and mindfulness may help in management of CRF, however, adherence to such interventions remains poor and there is little evidence for combining these interventions or for digital delivery. Few interventions have targeted women who have gynaecological cancer. This study developed and assessed the feasibility of digitally delivering mindfulness and exercise interventions to manage CRF in this population.</div></div><div><h3>Methods</h3><div>An 8-week feasibility randomised control trial was delivered via a mobile app to two groups (mindfulness only; mindfulness and exercise). Feasibility was assessed through retention, adherence and attrition rates. Participant-reported outcome measures (PROMs) for fatigue, anxiety, depression, sleep and health-related quality of life were collected pre and post intervention and analysed using descriptive statistics (mean, median, inter-quartile ranges and line graphs). Online focus groups explored patient experiences, acceptability and satisfaction with the interventions.</div></div><div><h3>Results</h3><div>Twenty-five participants (mindfulness only n = 13, mindfulness and exercise n = 12) had overall retention rate of 88 %, adherence was 72.72 % and attrition was 12 %. Both groups demonstrated improvements in fatigue (mindfulness-alone; 7.8, mindfulness and exercise 14.11), anxiety (2.9; 4.87), depression (2.06; 4.26), sleep, (2.8; 2.71), and HRQOL (6.4; 10.4), based on changes in mean scores. Qualitative findings identified three main themes: benefits of participation, barriers to participation and digital delivery of the intervention.</div></div><div><h3>Conclusion</h3><div>Both groups experienced improvements in CRF, anxiety, depression, sleep and HRQoL. Retention and adherence rates were high with a good level of app engagement. Feasibility was demonstrated through retention, adherence and attrition rates and interventions were deemed acceptable. These findings suggest that a fully powered RCT is warranted. While online recruitment was challenging, the online delivery of interventions enabled broader participant inclusion and scalability.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101807"},"PeriodicalIF":1.2,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144685697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing delays in accessing and completing radiotherapy for cervical cancer treatment: A multicenter survey of oncology providers in go further-funded countries in Sub-Saharan Africa","authors":"Caroline G. Kernell ,&nbsp;Megan Kassick ,&nbsp;Jessica M. George ,&nbsp;Chidinma P. Anakwenze ,&nbsp;Edward L. Trimble ,&nbsp;Surbhi Grover","doi":"10.1016/j.gore.2025.101810","DOIUrl":"10.1016/j.gore.2025.101810","url":null,"abstract":"<div><h3>Objective</h3><div>Cervical cancer is a leading cause of cancer death in Sub-Saharan Africa. Go Further provides funds for prevention and screening in Sub-Saharan Africa, but access to treatment for invasive disease remains limited. This survey aims to assess delays in accessing curative-intent chemoradiotherapy for cervical cancer in countries receiving Go Further funding.</div></div><div><h3>Methods</h3><div>Oncology providers in countries receiving Go Further funding (Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Tanzania, Uganda, Zambia, Zimbabwe) and South Africa were invited to participate in a web-based survey beginning September 2023.</div></div><div><h3>Results</h3><div>Fifteen oncology providers responded, with all countries except Malawi represented. Nearly half (46.3 %) reported wait time of ≥two months for chemoradiotherapy consultation. 93.3 %, 71.4 %, 53.7 % and 73.3 % had access to at least one CT, linear accelerator, cobalt, and brachytherapy machine, respectively. Majority (60 %) reported wait time of &lt;one month to initiate chemoradiotherapy after staging. However, 28.6 % reported &gt;95 % of patients complete external radiotherapy within 42 days, and 33 % reported &gt;95 % of these patients receive brachytherapy. Only 26.7 % reported overall treatment time within 56 days for &gt;95 % of patients. Lack of transportation, funding, and patient fear, were other treatment barriers reported.</div></div><div><h3>Conclusion</h3><div>These results highlight the need for additional chemoradiotherapy resources in Go Further-funded countries. In addition to expanding radiotherapy, supplemental avenues to improve access in Sub-Saharan Africa include addressing barriers that increase wait times along the care continuum and implementing social support. This survey serves as a call to Go Further, highlighting the urgent need for resource allocation for cervical cancer treatment.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101810"},"PeriodicalIF":1.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The added value of chemotherapy after secondary cytoreductive surgery in unifocal versus multifocal first recurrent epithelial ovarian cancer: A systematic review","authors":"R.E.W.M. van de Vorst ,&nbsp;M.D. Huiskamp ,&nbsp;E.H. Gort ,&nbsp;P.O. Witteveen ,&nbsp;R.P. Zweemer ,&nbsp;C.G. Gerestein","doi":"10.1016/j.gore.2025.101809","DOIUrl":"10.1016/j.gore.2025.101809","url":null,"abstract":"<div><h3>Objective</h3><div>This systematic review aims to evaluate the added value of chemotherapy after secondary cytoreductive surgery (SCS) on survival in patients with unifocal and multifocal first recurrent epithelial ovarian cancer (EOC). Moreover, it compares survival outcomes between unifocal and multifocal recurrences in treatment outcomes.</div></div><div><h3>Methods</h3><div>A systematic search was conducted across PubMed, Embase, and the Cochrane Library identified 907 articles. Studies were selected if they involved patients with first recurrent EOC undergoing SCS, stratified by unifocal or multifocal recurrence. The primary outcomes were progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>No studies specifically addressed the added value of chemotherapy after SCS in unifocal versus multifocal first recurrent EOC. This systematic review identified eight studies examining PFS and OS in patients with unifocal and multifocal first recurrent EOC following SCS with chemotherapy. Findings consistently show that unifocal first recurrent EOC is associated with significantly improved PFS and OS compared to multifocal first recurrent EOC. However, the extent of the survival benefit varied. Six studies showed an advantage for unifocal recurrence on multivariate analyses, although two studies did not find statistically significant differences after adjusting for other variables.</div></div><div><h3>Conclusion</h3><div>This review shows that there is a knowledge gap regarding the added value of chemotherapy after complete SCS in first recurrent EOC. However, this review shows a survival advantage of unifocal over multifocal first recurrent EOC. There is a need for clinical trials to compare survival outcomes between unifocal and multifocal first recurrent EOC patients undergoing SCS alone or SCS with chemotherapy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101809"},"PeriodicalIF":1.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiologic and surgical peritoneal cancer index in patients with low grade serous ovarian carcinoma","authors":"Rachel R. Pacyna ,&nbsp;Leah Thomas ,&nbsp;Nisa C. Oren ,&nbsp;Josephine S. Kim","doi":"10.1016/j.gore.2025.101805","DOIUrl":"10.1016/j.gore.2025.101805","url":null,"abstract":"<div><h3>Background</h3><div>Peritoneal cancer index (PCI) is a numerical score that quantifies tumor extent in colorectal cancers. More recently it has been applied to ovarian cancers. However, the prognostic value of PCI in patients with low grade serous ovarian carcinoma (LGSOC) is not well characterized. We investigated whether pre-operative CT imaging could predict intraoperative disease extent and outcomes in LGSOC patients using PCI. We also investigated the association between PCI scores and cytoreduction outcomes.</div></div><div><h3>Methods</h3><div>Advanced stage LGSOC who had undergone preoperative CT imaging, cytoreductive surgery, and follow-up in the study timeframe were included. PCI was calculated based on the Sugarbaker method (<span><span>Harmon &amp; Sugarbaker, 2005</span></span>). A blinded radiologist calculated CT-PCI scores. Surgical PCI was calculated retrospectively from operative reports. The relationship between CT-PCI and surgical PCI was determined using univariate linear regression. Surgical and survival outcomes were assessed.</div></div><div><h3>Results</h3><div>For 21 patients (median age at cancer diagnosis = 58 years old, interquartile range (IQR) = 54–69), mean CT-PCI was 13 (SD: 8). Mean surgical PCI was 12 (SD: 7). CT-PCI significantly predicted surgical PCI (beta-coefficient = 0.59, p-value = 0.001). CT-PCI overestimated surgical PCI in 71 % of patients. Neither CT-PCI nor surgical PCI were significantly associated with optimal cytoreduction, though a trend was observed toward higher PCI scores in patients who were sub-optimally cytoreduced.</div></div><div><h3>Conclusion</h3><div>CT-PCI significantly predicts surgical PCI in a small, retrospective cohort of patients with LGSOC. CT-PCI may be useful to estimate surgical PCI and possibly cytoreductive outcome in LGSOC. However, CT-PCI can overestimate surgical PCI and should not be used to preclude LGSOC patients from a cytoreduction attempt.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101805"},"PeriodicalIF":1.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144696441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome","authors":"Shilpa Mokshagundam ,&nbsp;Mrinal M. Patnaik ,&nbsp;Luigi A. DeVitis ,&nbsp;Simrit K. Warring ,&nbsp;Megan E. Grudem ,&nbsp;Matthew S. Block","doi":"10.1016/j.gore.2025.101806","DOIUrl":"10.1016/j.gore.2025.101806","url":null,"abstract":"<div><h3>Objective</h3><div>As the use of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) increases in the management of advanced ovarian cancer, therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may be observed more frequently. Strategies for management of this unique condition are needed.</div></div><div><h3>Methods</h3><div>In this case report, we demonstrate the case of a patient with advanced ovarian cancer and a pathogenic BRCA1 mutation who developed MDS following 4 years of maintenance PARPi.</div></div><div><h3>Results</h3><div>Management of therapy-related MDS/AML is variable. In addition, subsequent oncologic treatments may be limited due to risk of MDS/AML recurrence with exposure to cytotoxic therapies and/or PARPi. Risk for MDS/AML recurrence can be monitored and predicted by evaluation for clonal hematopoiesis. This patient underwent autologous stem cell transplant. After subsequent disease recurrence, she underwent repeat germline testing which showed BRCA1 wildtype. In addition, no clonal hematopoietic clones were identified using a specialized institutional assay. For this reason and given previous durable response to PARPi, the patient was re-treated with a PARPi.</div></div><div><h3>Conclusions</h3><div>This case highlights the unique management of therapy-related MDS/AML and underscores the importance of multidisciplinary care in determining safety of subsequent cancer-directed therapies in this patient population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101806"},"PeriodicalIF":1.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}